Literature DB >> 16985596

Prostate cancer and chemotherapy.

Masood A Khan, Alan W Partin.   

Abstract

Entities:  

Year:  2004        PMID： 16985596      PMCID： PMC1472829     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  12 in total

Review 1.  Optimal hormonal therapy for advanced prostatic carcinoma.

Authors:  S Goktas; E D Crawford
Journal:  Semin Oncol       Date:  1999-04       Impact factor: 4.929

Review 2.  Targeting apoptosis in prostate cancer.

Authors:  R S DiPaola; J Patel; M M Rafi
Journal:  Hematol Oncol Clin North Am       Date:  2001-06       Impact factor: 3.722

Review 3.  Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

Authors:  E J Small; N J Vogelzang
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

4.  Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure.

Authors:  G E Hanks; J M Krall; A L Hanlon; S O Asbell; M V Pilepich; J B Owen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-01-01       Impact factor: 7.038

Review 5.  Advantages of total androgen blockade in the treatment of advanced prostate cancer.

Authors:  J Geller; J Albert; A Vik
Journal:  Semin Oncol       Date:  1988-04       Impact factor: 4.929

6.  Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.

Authors:  Gwenaelle Gravis; Franck Bladou; Naji Salem; Geneviève Macquart-Moulin; Gérard Serment; Jacques Camerlo; Dominique Genre; Valérie-Jeanne Bardou; Dominique Maraninchi; Patrice Viens
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

Review 7.  The evolving role of docetaxel in the management of androgen independent prostate cancer.

Authors:  Masood A Khan; Michael A Carducci; Alan W Partin
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

Review 8.  Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.

Authors:  H Calvert; I Judson; W J van der Vijgh
Journal:  Cancer Surv       Date:  1993

9.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

Authors:  H Zincke; J E Oesterling; M L Blute; E J Bergstralh; R P Myers; D M Barrett
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

10.  Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.

Authors:  A Nehmé; P Varadarajan; G Sellakumar; M Gerhold; H Niedner; Q Zhang; X Lin; R D Christen
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.